Clorsulon

製品コードS2613 バッチS261302

印刷

化学情報

Chemical Structure Synonyms MK-401,L631529 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C8H8Cl3N3O4S2
分子量 380.66 CAS No. 60200-06-8
Solubility (25°C)* 体外 DMSO 76 mg/mL (199.65 mM)
Ethanol 7 mg/mL (18.38 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Clorsulon (MK-401,L631529) is used in the treatment of Fasciola hepatica infections in calves and sheep.
in vitro

Clorsulon is a competitive inhibitor of both 3-phosphoglycorate and ATP and had a Ki of 0.29 mM, inhibits glucose utilization and acetate and propionate formation by mature Fasciola hepatica in vitro. [1]
in vivo

Clorsulon (a single dose of 15 mg/kg) is effective in removing over 90% of immature Fasciola hepatica from sheep (6 weeks after infection) and calves (8 weeks after infection). A 2.5 mg/kg dose removed over 90% of mature (16 weeks old) liver fluke from sheep. [1] Clorsulon causes severe disruption to the tegument and gut of Fasciola hepatica after in vivo incubation. [3]

プロトコル(参考用のみ)

キナーゼアッセイ phosphoglycerate kinase
Phosphoglycerate kinase is assayed in the back-reaction. Reaction mixtures in 0.5 ml contained the following: triethanolamine-C1 (pH 8.5) 15 μmol; magnesium chloride 5.0 μmol; DTT 2.5 μmol; EDTA 0.2 μmol; NADH, 0.1 μmol; sodium chloride, 25/μmol; 3-phosphoglyceric acid (3-PGA), 5μmol; ATP, 1μmol; glyceraldehyde- 3-phosphate dehydrogenase, 4 I.U. Reaction is at 20 °C and is initiated after 5 min incubation by addition of 3-PGA. The reaction is monitored at 340 nm on a Beckman ACTA C III recording spectrophotometer equipped with an automatic sample changer. In the presence of MK-401, the reaction is monitored at 366 nm rather than 340 nm to avoid interference due to absorbance by the aromatic systems.
動物実験 動物モデル Rat
投薬量 12.5 mg/kg
投与方法 Orally

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258] PubMed: 35207746
Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome [ Hum Cell, 2022, 10.1007/s13577-022-00671-y] PubMed: 35118583
Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma [ Hum Cell, 2021, 34(6):1911-1918] PubMed: 34383271
Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00579-z] PubMed: 34304386
Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00639-4] PubMed: 34731453
Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors. [ Cancer Cell Int, 2020, 19;20:58] PubMed: 32099531
Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor [ Hum Cell, 2020, 10.1007/s13577-020-00425-8] PubMed: 32886306
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma [ Hum Cell, 2020, 10.1007/s13577-020-00420-z] PubMed: 32870449

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。